Pulse Check: Pharmaceuticals Roundup.
According to JP Morgan equity derivatives strategist Marko Kolanovic and biotechnology analyst Cory Kasimov, investors should buy option of Dendrean Corp because the FDA is likely going to approve its prostrate cancer therapy drug Provenge, next month and boost the stock price to a record. "We remain very optimistic (90 percent probability) that Provenge will be approved on time" the analysts wrote in a report.
news items from dendreon site
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.005(1.28%) |
Mkt cap ! $573.7M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 40.0¢ | 38.5¢ | $1.022M | 2.599M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17394 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 60247 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |